1 Hirata H, "p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies" 69 : 780-790, 1997
2 Jin H, "a-Synuclein negatively regulates protein kinase Cd expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity" 31 : 2035-2051, 2011
3 Ajjimaporn A, "Zinc rescues dopaminergic SK-N-SH cell lines from methamphetamine-induced toxicity" 77 : 361-366, 2008
4 United Nations Office on Drugs and Crime, "World Drug Report 2015" United Nations
5 Moszczynska A, "Why is Parkinsonism not a feature of human methamphetamine users?" 127 : 363-370, 2004
6 Kaul S, "Tyrosine phosphorylation regulates the proteolytic activation of protein kinase Cdelta in dopaminergic neuronal cells" 280 : 28721-28730, 2005
7 Sonsalla PK, "Treatment of mice with methamphetamine produces cell loss in the substantia nigra" 738 : 172-175, 1996
8 Seddigh R, "Treating methamphetamine-induced resistant psychosis with clozapine" 2014 : 845145-, 2014
9 Jin H, "Transcriptional regulation of pro-apoptotic protein kinase Cdelta: implications for oxidative stress-induced neuronal cell death" 286 : 19840-19859, 2011
10 Speidel D, "Transcription-independent p53 apoptosis: an alternative route to death" 20 : 14-24, 2010
11 Walker J, "Total antioxidant capacity is significantly lower in cocaine-dependent and methamphetamine-dependent patients relative to normal controls: results from a preliminary study" 29 : 537-543, 2014
12 Johnson-Davis KL, "The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity" 482 : 151-154, 2003
13 Itzhak Y, "The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo" 67 : 1770-1773, 1996
14 Remington G, "The neurobiology of relapse in schizophrenia" 152 : 381-390, 2014
15 Hsieh JH, "The neurobiology of methamphetamine induced psychosis" 8 : 537-, 2014
16 Barr AM, "The need for speed: an update on methamphetamine addiction" 31 : 301-313, 2006
17 Hastrup H, "The human dopamine transporter forms a tetramer in the plasma membrane: crosslinking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs" 278 : 45045-45048, 2003
18 Eichenbaum H, "The hippocampus and declarative memory:cognitive mechanisms and neural codes" 127 : 199-207, 2001
19 Heysieattalab S, "The effects of GABAA and NMDA receptors in the shell-accumbens on spatial memory of METHtreated rats" 142 : 23-35, 2016
20 Simon SL, "The effect of relapse on cognition in abstinent methamphetamine abusers" 27 : 59-66, 2004
21 Yamada H, "The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens" 1131 : 88-96, 2007
22 Peter D, "The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors" 269 : 7231-7237, 1994
23 Harris AC, "The anti-(?)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (?)-methamphetamine effects on intracranial self-stimulation in rats" 10 : e0118787-, 2015
24 Pakkenberg B, "The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method" 54 : 30-33, 1991
25 Sucic S, "The N terminus of monoamine transporters is a lever required for the action of amphetamines" 285 : 10924-10938, 2010
26 Chen YJ, "Tetrahydropalmatine protects against methamphetamine-induced spatial learning and memory impairment in mice" 28 : 222-232, 2012
27 Damghani F, "Swimming exercise attenuates psychological dependence and voluntary methamphetamine consumption in methamphetamine withdrawn rats" 19 : 594-600, 2016
28 Yui K, "Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis" 914 : 292-302, 2000
29 Castino R, "Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine" 106 : 1426-1439, 2008
30 Stephans SE, "Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum" 71 : 613-621, 1998
31 Wang Q, "Subpicomolar diphenyleneiodonium inhibits microglial NADPH oxidase with high specificity and shows great potential as a therapeutic agent for neurodegenerative diseases" 62 : 2034-2043, 2014
32 Yui K, "Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia" 914 : 1-12, 2000
33 Thompson PM, "Structural abnormalities in the brains of human subjects who use methamphetamine" 24 : 6028-6036, 2004
34 Eisch AJ, "Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine" 598 : 321-326, 1992
35 Wilson JM, "Striatal dopamine nerve terminal markers in human, chronic methamphetamine users" 2 : 699-703, 1996
36 Gross NB, "Striatal dopamine D1 and D2receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity" 65 : 1144-1155, 2011
37 Yui K, "Stress induced spontaneous recurrence of methamphetamine psychosis: the relation between stressful experiences and sensitivity to stress" 58 : 67-75, 2000
38 Ujike H, "Stimulant-induced psychosis and schizophrenia: the role of sensitization" 4 : 177-184, 2002
39 Dai H, "Social isolation stress significantly enhanced the disruption of prepulse inhibition in mice repeatedly treated with methamphetamine" 1025 : 257-266, 2004
40 Lu P, "Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment" 207 : 387-393, 2010
41 Morgan ME, "Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extrastriatal dopaminergic nuclei" 19 : 989-995, 1980
42 Bisagno V, "Short toxic methamphetamine schedule impairs object recognition task in male rats" 940 : 95-101, 2002
43 Reichel CM, "Sex differences in escalation of methamphetamine self-administration: cognitive and motivational consequences in rats" 223 : 371-380, 2012
44 Imam SZ, "Selenium, an antioxidant, protects against methamphetamineinduced dopaminergic neurotoxicity" 818 : 575-578, 1999
45 Imam SZ, "Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation" 855 : 186-191, 2000
46 Kim HC, "Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss;comparison with MPTP model" 862 : 247-252, 2000
47 Granado N, "Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine" 18 : 48-58, 2010
48 Kaneko Y, "Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine" 32 : 658-664, 2007
49 Battaglia G, "Selective blockade of mGlu5metabotropic glutamate receptors is protective against methamphetamine neurotoxicity" 22 : 2135-2141, 2002
50 Wu XF, "S-Nitrosylating protein disulphide isomerase mediates a-synuclein aggregation caused by methamphetamine exposure in PC12 cells" 230 : 19-27, 2014
51 Seemann S, "Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity" 24 : 3853-3863, 2005
52 Shimazoe T, "Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization" 388 : 249-254, 2000
53 Sonsalla PK, "Roles of D1 and D2dopamine receptor subtypes in mediating the methamphetamineinduced changes in monoamine systems" 238 : 932-937, 1986
54 Nakajima A, "Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity" 24 : 2212-2225, 2004
55 Kanthasamy AG, "Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis" 5 : 609-620, 2003
56 Shin EJ, "Role of oxidative stress in methamphetamineinduced dopaminergic toxicity mediated by protein kinase Cd" 232 : 98-113, 2012
57 Di Monte DA, "Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase" 67 : 2443-2450, 1996
58 Shin EJ, "Role of microsomal epoxide hydrolase in methamphetamine-induced drug dependence in mice" 87 : 3679-3686, 2009
59 Fumagalli F, "Role of dopamine transporter in methamphetamine-induced neurotoxicity:evidence frommice lacking the transporter" 18 : 4861-4869, 1998
60 Clemens KJ, "Repeated weekly exposure to MDMA, methamphetamine or their combination:long-term behavioural and neurochemical effects in rats" 86 : 183-190, 2007
61 Nagai T, "Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol" 194 : 21-32, 2007
62 Kamei H, "Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice" 59 : 75-84, 2006
63 O’Dell SJ, "Repeated administration of methamphetamine damages cells in the somatosensory cortex: overlap with cytochrome oxidase-rich barrels" 37 : 32-37, 2000
64 Brodie C, "Regulation of cell apoptosis by protein kinase c delta" 8 : 19-27, 2003
65 Tsuji T, "Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen" 34 : 764-774, 2009
66 Guillot TS, "Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis" 106 : 2205-2217, 2008
67 Frey K, "Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine" 334 : 273-279, 1997
68 McCann UD, "Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users:evidence from positron emission tomography studies with [11C]WIN-35,428" 18 : 8417-8422, 1998
69 Schultz CC, "Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia" 36 : 1747-1753, 2011
70 Melega WP, "Recovery of striatal dopamine function after acute amphetamine-and METH-induced neurotoxicity in the vervet monkey" 766 : 113-120, 1997
71 Cass WA, "Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine" 19 : 7653-7660, 1999
72 Harvey DC, "Recovery from methamphetamine induced long-term nigrostriatal dopaminergicdeficits without substantia nigra cell loss" 871 : 259-270, 2000
73 Whitehead RE, "Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter" 76 : 1242-1251, 2001
74 Srisurapanont M, "Psychotic symptoms in methamphetamine psychotic inpatients" 6 : 347-352, 2003
75 Cervinski MA, "Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms" 280 : 40442-40449, 2005
76 Lieberman JA, "Provocative tests with psychostimulant drugs in schizophrenia" 91 : 415-433, 1987
77 Gordon R, "Protein kinase Cd upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson’s disease" 93 : 96-114, 2016
78 Hashimoto K, "Protective effects on N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine" 29 : 2018-2023, 2004
79 Chen H, "Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine" 222 : 37-45, 2012
80 Wu CF, "Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice" 76 : 103-109, 2003
81 Hashimoto K, "Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys" 61 : 577-581, 2007
82 Zhang L, "Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine" 30 : 1381-1393, 2006
83 Hozumi H, "Protective effects of interferon-gamma against methamphetamine-induced neurotoxicity" 177 : 123-129, 2008
84 Kim HC, "Protection of methamphetamine nigrostriatal toxicity by dietary selenium" 851 : 76-86, 1999
85 Rendell PG, "Prospective memory impairment in former users of methamphetamine" 203 : 609-616, 2009
86 Segal DS, "Prolonged exposure of rats to intravenous methamphetamine:behavioral and neurochemical characterization" 180 : 501-512, 2005
87 Lecomte T, "Profiles of individuals seeking psychiatric help for psychotic symptoms linked to methamphetamine abuse—baseline results from the MAPS (methamphetamine and psychosis study)" 3 : 168-181, 2010
88 Henry BL, "Prepulse inhibition in HIV-1 gp120transgenic mice after withdrawal from chronic methamphetamine" 25 : 12-22, 2014
89 Lominac KD, "Prefrontal glutamate correlates of methamphetamine sensitization and preference" 43 : 689-702, 2016
90 Chen CK, "Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis" 33 : 1407-1414, 2003
91 Jung BD, "Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration" 56 : 229-244, 2010
92 Wang Q, "Post-treatment with ultralow dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson’s disease models" 138 : 1247-1262, 2015
93 Bowyer JF, "Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation" 919 : 179-183, 2001
94 Grace AA, "Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia" 41 : 1-24, 1991
95 Hyoung-Chun Kim, "Pharmacological Action of Panax Ginseng on the Behavioral Toxicities Induced by Psychotropic Agents" 대한약학회 28 (28): 995-1001, 2005
96 McCann UD, "Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users" 62 : 91-100, 2008
97 Baumann MH, "Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate" 301 : 1190-1197, 2002
98 Son JH, "Perseverative behavior in rats with methamphetamine-induced neurotoxicity" 67 : 95-103, 2013
99 Imam SZ, "Peroxynitrite plays a role in methamphetamineinduced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase" 76 : 745-749, 2001
100 Park SU, "Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons" 22 : 4399-4405, 2002
101 Yoshida K, "PKCdelta signaling: mechanisms of DNA damage response and apoptosis" 19 : 892-901, 2007
102 Shin EJ, "PKCd inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment" 59 : 39-50, 2011
103 Tran TV, "PKCd gene facilitates cognitive impairment induced by low doses of methamphetamine (MA) in mice" 19 (19): 50-, 2016
104 Di Giacomo V, "PKC-d signalling pathway is involved in H9c2cells differentiation" 80 : 204-212, 2010
105 Huang MC, "Oxidative stress status in recently abstinent methamphetamine abusers" 67 : 92-100, 2013
106 Solhi H, "Oxidative stress and lipid peroxidation in prolonged users of methamphetamine" 7 : 79-82, 2014
107 Cunha-Oliveira T, "Oxidative stress and drugs of abuse: an update" 10 : 321-334, 2013
108 Winyard PG, "Oxidative activation of antioxidant defence" 30 : 453-461, 2005
109 Abekawa T, "Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex" 101 : 84-94, 2008
110 Fornai F, "Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice" 65 : 405-413, 2005
111 Granado N, "Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum" 59 : 1850-1863, 2011
112 Ohno M, "Nitric oxide synthase inhibitors block behavioral sensitization to methamphetamine in mice" 275 : 39-44, 1995
113 Mizoguchi H, "Nicotine ameliorates impairment of working memory in methamphetamine-treated rats" 220 : 159-163, 2011
114 O’Callaghan JP, "Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse" 270 : 741-751, 1994
115 Seiden LS, "Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections" 537 : 161-172, 1988
116 Schro¨der N, "Neurotoxic methamphetamine regimen severely impairs recognition memory in rats" 49 : 89-96, 2003
117 Thrash B, "Neurotoxic effects of methamphetamine" 35 : 171-179, 2010
118 Nordahl TE, "Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition:a review" 15 : 317-325, 2003
119 Kanthasamy K, "Neuroprotective effect of resveratrol against methamphetamine-induced dopaminergic apoptotic cell death in a cell culture model of neurotoxicity" 9 : 49-53, 2011
120 Golembiowska K, "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats" 45 : 484-492, 2003
121 Rusyniak DE, "Neurologic manifestations of chronic methamphetamine abuse" 36 : 261-275, 2013
122 Yui K, "Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization" 4 : 512-523, 1999
123 Gao HM, "NADPH oxidases: novel therapeutic targets for neurodegenerative diseases" 33 : 295-303, 2012
124 Qin L, "NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia" 279 : 1415-1421, 2004
125 Qin L, "NADPH oxidase and aging drive microglial activaton, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration" 61 : 855-868, 2013
126 Torres B, "N-terminus regulation of VMAT2mediates methamphetamine-stimulated efflux" 259 : 194-202, 2014
127 Khoshbouei H, "N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux" 2 : E78-, 2004
128 Shin EJ, "N-methyl, N-propynyl-2-phenylethylamine (MPPE), a selegiline analog, attenuates MPTP-induced dopaminergic toxicity with guaranteed behavioral safety: involvement of inhibitions of mitochondrial oxidative burdens and p53 gene-elicited pro-apoptotic change" 53 : 6251-6269, 2016
129 Zhang X, "N-acetylcysteine amide protects against methamphetamine-induced tissue damage in CD-1 mice" 31 : 931-944, 2012
130 Chen CK, "Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis" 136B : 87-91, 2005
131 Gonza´lez B, "Modafinil improves methamphetamine-induced object recognition deficits and restores prefrontal cortex ERK signaling in mice" 87 : 188-197, 2014
132 Raineri M, "Modafinil abrogates methamphetamine-induced neuroinflammation and apoptotic effects in the mouse striatum" 7 : e46599-, 2012
133 Endo H, "Mitochondrial translocation of p53 mediates release of cytochrome c and hippocampal CA1 neuronal death after transient global cerebral ischemia in rats" 26 : 7974-7983, 2006
134 Kroemer G, "Mitochondrial membrane permeabilization in cell death" 87 : 99-163, 2007
135 Barbosa DJ, "Mitochondria: key players in the neurotoxic effects of amphetamines" 89 : 1695-1725, 2015
136 Boger HA, "Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice" 33 : 459-466, 2009
137 Sriram K, "Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha" 96 : 706-718, 2006
138 Zhang W, "Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha synuclein" 55 : 1178-1188, 2007
139 Kreutzberg GW, "Microglia: a sensor for pathological events in the CNS" 19 : 312-318, 1996
140 Lieberman JA, "Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia" 11 : 107-118, 1994
141 Lee KW, "Methamphetaminesensitized mice are accompanied by memory impairment and reduction of N-methyl-D-aspartate receptor ligand binding in the prefrontal cortex and hippocampus" 178 : 101-107, 2011
142 Gonc¸alves J, "Methamphetamineinduced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain" 1139 : 103-111, 2008
143 Thrash-Williams B, "Methamphetamineinduced dopaminergic toxicity prevented owing to the neuroprotective effects of salicylic acid" 154 : 24-29, 2016
144 Curtin K, "Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment" 146 : 30-38, 2015
145 Sekine Y, "Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET" 158 : 1206-1214, 2001
146 Braren SH, "Methamphetamine-induced short-term increase and long-term decrease in spatial working memory affects protein Kinase M zeta (PKMf), dopamine, and glutamate receptors" 8 : 438-, 2014
147 Hirata H, "Methamphetamine-induced serotonin neurotoxicity is attenuated in p53-knockout mice" 768 : 345-348, 1997
148 Metzger RR, "Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia" 295 : 1077-1085, 2000
149 Lau JWS, "Methamphetamine-induced oxidative stress in cultured mouse astrocytes" 914 : 146-156, 2000
150 Lin M, "Methamphetamine-induced neurotoxicity linked to ubiquitinproteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells" 210 : 308-332, 2012
151 Ladenheim B, "Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6" 58 : 1247-1256, 2000
152 Asanuma M, "Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug" 352 : 13-16, 2003
153 De Vito MJ, "Methamphetamine-induced neuronal damage: a possible role for free radicals" 28 : 1145-1150, 1989
154 Asanuma M, "Methamphetamine-induced increase in striatal p53 DNA-binding activity is attenuated in Cu, Zn-superoxide dismutase transgenic mice" 325 : 191-194, 2002
155 Imam SZ, "Methamphetamine-induced dopaminergic neurotoxicity and production of peroxynitrite are potentiated in nerve growth factor differentiated pheochromocytoma 12 cells" 965 : 204-213, 2002
156 Guilarte TR, "Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity" 122 : 499-513, 2003
157 Reichel CM, "Methamphetamine-induced changes in the object recognition memory circuit" 62 : 1119-1126, 2012
158 Zhu JP, "Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice" 140 : 607-622, 2006
159 Deng X, "Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice" 83 : 121-124, 2000
160 Imam SZ, "Methamphetamine-induced alteration in striatal p53 and bcl-2expressions in mice" 91 : 174-178, 2001
161 Flora G, "Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation" 2 : 71-85, 2002
162 Grant KM, "Methamphetamine-associated psychosis" 7 : 113-139, 2012
163 Panenka WJ, "Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings" 129 : 167-179, 2013
164 Callaghan RC, "Methamphetamine use and schizophrenia: a population-based cohort study in California" 169 : 389-396, 2012
165 Maragos WF, "Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase" 878 : 218-222, 2000
166 Kousik SM, "Methamphetamine selfadministration results in persistent dopaminergic pathology:implications for Parkinson’s disease risk and reward-seeking" 40 : 2707-2714, 2014
167 McFadden LM, "Methamphetamine selfadministration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure" 340 : 295-303, 2012
168 Krasnova IN, "Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat" 5 : e8790-, 2010
169 Glasner-Edwards S, "Methamphetamine psychosis:epidemiology and management" 28 : 1115-1126, 2014
170 Eisch AJ, "Methamphetamine neurotoxicity:dissociation of striatal dopamine terminal damage from parietal cortical cell body injury" 30 : 433-445, 1998
171 Davidson C, "Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment" 36 : 1-22, 2001
172 Cubells JF, "Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress" 14 : 2260-2271, 1994
173 Thomas DM, "Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation" 311 : 1-7, 2004
174 Belcher AM, "Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens" 33 : 1453-1463, 2008
175 Marshall JF, "Methamphetamine influences on brain and behavior: unsafe at any speed?" 35 : 536-545, 2012
176 Jayanthi S, "Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades" 18 : 238-251, 2004
177 Baucum AJ 2nd, "Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism" 24 : 3436-3443, 2004
178 Nair MP, "Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells" 4 : 129-139, 2009
179 Liang H, "Methamphetamine enhances HIV infection of macrophages" 172 : 1617-1624, 2008
180 Kalechstein AD, "Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence" 15 : 215-220, 2003
181 Simon SL, "Methamphetamine dependence and neuropsychological functioning:evaluating change during early abstinence" 71 : 335-344, 2010
182 Deng X, "Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method" 93 : 64-69, 2001
183 Sekine Y, "Methamphetamine causes microglial activation in the brains of human abusers" 28 : 5756-5761, 2008
184 Ac¸ikgo¨z O, "Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum" 813 : 200-202, 1998
185 Jayanthi S, "Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex" 15 : 1745-1752, 2001
186 Ares-Santos S, "Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining" 39 : 1066-1080, 2014
187 Burrows KB, "Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex" 27 : 133-144, 1997
188 Mahajan SD, "Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1neuropathogenesis in the context of drug abuse" 1203 : 133-148, 2008
189 Chipana C, "Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents" 54 : 1254-1263, 2008
190 Wu J, "Melatonin treatment during the incubation of sensitization attenuates methamphetamine-induced locomotor sensitization and MeCP2 expression" 65 : 145-152, 2016
191 Hirata H, "Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain" 30 : 150-155, 1998
192 Hirsch E, "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease" 334 : 345-348, 1988
193 Sulzer D, "Mechanisms of neurotransmitter release by amphetamines: a review" 75 : 406-433, 2005
194 Riddle EL, "Mechanisms of methamphetamine-induced dopaminergic neurotoxicity" 8 : E413-E418, 2006
195 Dluzen DE, "Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity" 9 : 40-44, 2011
196 Darke S, "Major physical and psychological harms of methamphetamine use" 27 : 253-262, 2008
197 Thomas DM, "MK-801 and dextromethorphan block microglial activation and protect against methamphetamineinduced neurotoxicity" 1050 : 190-198, 2005
198 Adams JP, "MAPK regulation of gene expression in the central nervous system" 60 : 377-394, 2000
199 Volkow ND, "Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex" 158 : 2015-2021, 2001
200 Reichel CM, "Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5" 36 : 782-792, 2011
201 Volkow ND, "Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence" 21 : 9414-9418, 2001
202 Akiyama K, "Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence" 1074 : 125-134, 2006
203 Hodges AB, "Long-term protective effects of methamphetamine preconditioning against single-day methamphetamine toxic challenges" 9 : 35-39, 2011
204 Melega WP, "Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles" 33 : 1441-1452, 2008
205 Chiu HY, "Long-lasting alterations in 5-HT2A receptor after a binge regimen of methamphetamine in mice" 17 : 1647-1658, 2014
206 Hotchkiss AJ, "Long term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain" 214 : 257-262, 1980
207 Nguyen XK, "Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCd gene" 58 : 86-106, 2015
208 Fitzmaurice PS, "Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine" 319 : 703-709, 2006
209 Nakato Y, "Lamotrigine blocks the initiation and expression of repeated high-dose methamphetamine-induced prepulse inhibition deficit in rats" 481 : 183-187, 2010
210 Miyamoto Y, "Knockdown of dopamine D2 receptors in the nucleus accumbens core suppresses methamphetamine-induced behaviors and signal transduction in mice" 18 : pyu038-, 2014
211 Friend DM, "Is there a role for nitric oxide in methamphetamine-induced dopamine terminal degeneration?" 25 : 153-160, 2014
212 Arai S, "Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen" 33 : 3164-3175, 2008
213 Beauvais G, "Involvement of dopamine receptors in binge methamphetamineinduced activation of endoplasmic reticulum and mitochondrial stress pathways" 6 : e28946-, 2011
214 Saha K, "Intracellular methamphetamine prevents the dopamine-induced enhancement of neuronal firing" 289 : 22246-22257, 2014
215 Dang DK, "Inhibition of protein kinase (PK) Cd attenuates methamphetamine-induced dopaminergic toxicity via upregulation of phosphorylation of tyrosine hydroxylase at Ser40 by modulation of protein phosphatase 2A and PKA" 42 : 192-201, 2015
216 Xu W, "Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors" 58 : 110-121, 2005
217 Boileau I, "Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?" 28 : 9850-9856, 2008
218 Callaghan RC, "Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs" 120 : 35-40, 2012
219 Fumagalli F, "Increased METH neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice" 19 : 2424-2431, 1999
220 Callaghan RC, "Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders" 25 : 2333-2339, 2010
221 Shiba T, "In vivo imaging of mitochondrial function in methamphetamine-treated rats" 57 : 866-872, 2011
222 Jiang J, "In vivo effects of methamphetamine on HIV-1 replication: a population-based study" 159 : 246-254, 2016
223 Mizoguchi H, "Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice" 196 : 233-241, 2008
224 Belcher AM, "Impaired object recognition memory following methamphetamine, but not pchloroamphetamine-or d-amphetamine-induced neurotoxicity" 30 : 2026-2034, 2005
225 Salamanca SA, "Impact of methamphetamine on infection and immunity" 8 : 445-, 2015
226 Kigerl KA, "Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord" 29 : 13435-13444, 2009
227 Cen X, "Identification of Piccolo as a regulator of behavioral plasticity and dopamine transporter internalization" 13 : 451-463, 2008
228 Huang CL, "Hydrogen peroxide induces loss of dopamine transporter activity: a calcium-dependent oxidative mechanism" 86 : 1247-1259, 2003
229 Theodore S, "Human immunodeficiency virus-1 protein tat and methamphetamine interactions" 1074 : 178-190, 2006
230 Maragos WF, "Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function" 83 : 955-963, 2002
231 Anglin MD, "History of the methamphetamine problem" 32 : 137-141, 2000
232 Mark KA, "High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity" 24 : 11449-11456, 2004
233 Motbey CP, "High levels of intravenous mephedrone (4-methylmethcathinone)self-administration in rats: neural consequences and comparison with methamphetamine" 27 : 823-836, 2013
234 Borgmann K, "HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads" 6 : 1143-, 2015
235 Cass WA, "HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat" 984 : 133-142, 2003
236 Shin EJ, "Ginsenosides attenuate methamphetamine-induced behavioral side effects in mice via activation of adenosine A2A receptors: possible involvements of the striatal reduction in AP-1 DNA binding activity and proenkephalin gene expression" 158 : 143-157, 2005
237 Shin EJ, "Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cd gene" 49 : 1400-1421, 2014
238 Nam Y, "Ginsenoside Re protects methamphetamine-induced mitochondrial burdens and proapoptosis via genetic inhibition of protein kinase C d in human neuroblastoma dopaminergic SH-SY5Y cell lines" 35 : 927-944, 2015
239 Chanasong R, "Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population" 551 : 58-61, 2013
240 Okochi T, "Genetic association analysis of NOS3 and methamphetamine-induced psychosis among Japanese" 9 : 151-154, 2011
241 Okumura T, "Genetic association analysis of NOS1 and methamphetamineinduced psychosis among Japanese" 9 : 155-159, 2011
242 Noda Y, "Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems" 13 : 1343-1354, 2010
243 Panicker N, "Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson’s Disease" 35 : 10058-10077, 2015
244 Bowyer JF, "Further studies of the role of hyperthermia in methamphetamine neurotoxicity" 268 : 1571-1580, 1994
245 Pirompul N, "Farnesyltransferase inhibitor attenuates methamphetamine toxicity-induced Ras proteins activation and cell death in neuroblastoma SHSY5Y cells" 545 : 138-143, 2013
246 Scofield MD, "Failure to recognize novelty after extended methamphetamine self-administration results from loss of long-term depression in the perirhinal cortex" 40 : 2526-2535, 2015
247 Schwendt M, "Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion" 331 : 555-562, 2009
248 Rogers JL, "Extended methamphetamine self-administration enhances reinstatement of drug seeking and impairs novel object recognition in rats" 199 : 615-624, 2008
249 Hadamitzky M, "Extended access to methamphetamine self-administration affects sensorimotor gating in rats" 217 : 386-390, 2011
250 Kim YH, "Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-delta (PKC-delta) signal pathway" 101 : 987-995, 2007
251 Ernst T, "Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study" 54 : 1344-1349, 2000
252 Kuczenski R, "Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat" 207 : 42-51, 2007
253 Segal DS, "Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge" 28 : 1730-1740, 2003
254 Saminathan H, "Environmental neurotoxic pesticide dieldrin activates a non receptor tyrosine kinase to promote PKCd-mediated dopaminergic apoptosis in a dopaminergic neuronal cell model" 32 : 567-577, 2011
255 Berg D, "Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons" 68 (68): 932-937, 2011
256 Wu CW, "Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SHSY5Y cells during methamphetamine induced apoptosis" 220 : 243-251, 2007
257 Wang Q, "Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice" 9 : 124-, 2012
258 Althobaiti YS, "Effects of repeated high-dose methamphetamine and ceftriaxone post-treatments on tissue content of dopamine and serotonin as well as glutamate and glutamine" 634 : 25-31, 2016
259 Chao YL, "Effects of repeated electroconvulsive shock on methamphetamine-induced behavioral abnormalities in mice" 5 : 393-401, 2012
260 Abekawa T, "Effects of nitric oxide (NO)synthesis inhibition on the development of supersensitivity to stereotypy and locomotion stimulating effects of methamphetamine" 679 : 200-204, 1995
261 Kuribara H, "Effects of dopamine antagonism on methamphetamine sensitization: evaluation by ambulatory activity in mice" 47 : 101-106, 1994
262 Sams-Dodd F, "Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats" 19 : 18-25, 1998
263 Abekawa T, "Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents" 125 : 77-87, 2011
264 Yoshimatsu A, "Effects of adenosine A1- and A2A-receptor agonists on enhancement of dopamine release from the striatum in methamphetamine-sensitized rats" 86 : 254-257, 2001
265 Pu C, "Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex" 23 : 328-334, 1996
266 Itzhak Y, "Effect of melatonin on methamphetamine-and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization" 37 : 781-791, 1998
267 Racay P, "Effect of ischemic preconditioning on mitochondrial dysfunction and mitochondrial p53 translocation after transient global cerebral ischemia in rats" 32 : 1823-1832, 2007
268 Fukami G, "Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine" 1016 : 90-95, 2004
269 Iijima M, "Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine" 246 : 24-28, 2013
270 Park MJ, "Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity" 1109 : 176-182, 2006
271 Grace CE, "Effect of a neurotoxic dose regimen of (?)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6mice" 32 : 346-355, 2010
272 Herring NR, "Effect of (?)-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats" 199 : 637-650, 2008
273 Latchoumycandane C, "Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKCd in cell culture and animal models of Parkinson’s disease" 256 : 314-323, 2011
274 Kuhn DM, "Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage" 1074 : 31-41, 2006
275 LaVoie MJ, "Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine" 19 : 1484-1491, 1999
276 Granado N, "Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA" 42 : 391-403, 2011
277 Kuribara H, "Dopamine D1 receptor antagonist SCH 23390retards methamphetamine sensitization in both combined administration and early posttreatment schedules in mice" 52 : 759-763, 1995
278 Ares-Santos S, "Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine" 45 : 810-820, 2012
279 Nakagawa Y, "Diversity and plasticity of microglial cells in psychiatric and neurological disorders" 154 : 21-35, 2015
280 Pucilowska J, "Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facialcutaneous and related syndromes" 32 : 8663-8677, 2012
281 Kai N, "Differential roles of dopamine D1 and D2 receptor-containing neurons of the nucleus accumbens shell in behavioral sensitization" 135 : 1232-1241, 2015
282 Itzhak Y, "Differential response of nNOS knockout mice to MDMA (‘‘ecstasy’’)- and methamphetamineinduced psychomotor sensitization and neurotoxicity" 1025 : 119-128, 2004
283 Brown JM, "Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression" 98 : 495-505, 2006
284 Ango F, "Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homer1 proteins and neuronal excitation" 20 : 8710-8716, 2000
285 Hayashi T, "Delta opioid peptide [D-Ala2, D-Leu5]enkephalin causes a near complete blockade of the neuronal damage caused by a single high dose of methamphetamine: examining the role of p53" 39 : 305-312, 2001
286 Bosse KE, "Deficits in behavioral sensitization and dopaminergic responses to methamphetamine in adenylyl cyclase 1/8-deficient mice" 135 : 1218-1231, 2015
287 Cass WA, "Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine" 280 : 105-113, 1997
288 Fallgatter AJ, "DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patientssupport for the glutamate hypothesis of schizophrenias" 9 : 489-497, 2010
289 Kita T, "Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption" 92 : 178-195, 2003
290 Gao HM, "Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease" 17 : 1954-1956, 2003
291 Mizuno M, "Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period" 1025 : 612-618, 2004
292 Sonsalla PK, "Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice" 256 : 506-512, 1991
293 Itzhak Y, "Comparison between the role of the neuronal and inducible nitric oxide synthase in methamphetamine-induced neurotoxicity and sensitization" 914 : 104-111, 2000
294 Bachmann RF, "Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamineinduced mitochondrial damage" 12 : 805-822, 2009
295 Simon SL, "Cognitive performance of current methamphetamine and cocaine abusers" 21 : 61-74, 2002
296 Simon SL, "Cognitive impairment in individuals currently using methamphetamine" 9 : 222-231, 2000
297 Johanson CE, "Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers" 185 : 327-338, 2006
298 Zarrabi H, "Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients" 16 : 44-, 2016
299 Ujike H, "Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis" 1025 : 279-287, 2004
300 Kalayasiri R, "Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C? T in a Thai treatment cohort" 109 : 965-976, 2014
301 Tata DA, "Chronic stress enhances methamphetamine-induced extracellular glutamate and excitotoxicity in the rat striatum" 62 : 325-336, 2008
302 Tomiyama G, "Chronic schizophrenia-like states in methamphetamine psychosis" 44 : 531-539, 1990
303 North A, "Chronic methamphetamine exposure produces a delayed, long-lasting memory deficit" 67 : 245-257, 2013
304 Fischer JF, "Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model" 208 : 203-209, 1979
305 Eisch AJ, "Characterizing cortical neuron injury with Fluoro-Jade labeling after a neurotoxic regimen of methamphetamine" 30 : 329-333, 1998
306 McConnell SE, "Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation" 50 : 131-141, 2015
307 Burrows KB, "Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines" 292 : 853-860, 2000
308 Kaul S, "Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP?)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration" 18 : 1387-1401, 2003
309 Koriem KM, "Caffeic acid protects tissue antioxidants and DNA content in methamphetamine induced tissue toxicity in Sprague Dawley rats" 23 : 134-143, 2013
310 Krasnova IN, "CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat" 58 : 132-143, 2013
311 Kish SJ, "Brain serotonin transporter in human methamphetamine users" 202 : 649-661, 2009
312 Sekine Y, "Brain serotonin transporter density and aggression in abstinent methamphetamine abusers" 63 : 90-100, 2006
313 Villemagne V, "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428positron emission tomography studies and direct in vitro determinations" 18 : 419-427, 1998
314 Mirecki A, "Brain antioxidant systems in human methamphetamine users" 8 : 1396-1408, 2004
315 Paulus MP, "Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects" 26 : 53-63, 2002
316 Wu PH, "Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum" 226 : 238-245, 2006
317 Ren Q, "BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms" 5 : e666-, 2015
318 Manning EE, "BDNF deficiency and youngadult methamphetamine induce sex-specific effects on prepulse inhibition regulation" 7 : 92-, 2013
319 Hermida-Ameijeiras A, "Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions" 45 : 103-116, 2004
320 Hirata H, "Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZnsuperoxide dismutase transgenic mice" 714 : 95-103, 1996
321 Cadet JL, "Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice" 62 : 380-383, 1994
322 Volkow ND, "Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers" 158 : 377-382, 2001
323 Newton TF, "Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers" 115 : 194-198, 2004
324 Nakamura K, "Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations" 120 : 243-252, 2006
325 Futamura T, "Aripiprazole attenuates established behavioral sensitization induced by methamphetamine" 34 : 1115-1119, 2010
326 Dang DK, "Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK" 13 : 12-, 2016
327 Maehara S, "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia" 91 : 140-149, 2008
328 Hogan KA, "Analysis of VMAT2binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations" 74 : 2217-2220, 2000
329 Rosario Moratalla, "Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms" Elsevier BV 155 : 149-170, 2017
330 Goodwin JS, "Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo" 284 : 2978-2989, 2009
331 Wagner GC, "Alphamethyltyrosine attenuates and reserpine increases METH-induced neuronal changes" 270 : 285-288, 1983
332 Truong JG, "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity" 314 : 1087-1092, 2005
333 Todd G, "Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism" 25 : 27-32, 2016
334 Sato M, "Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis" 18 : 429-440, 1983
335 Silva CD, "A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice" 25 : 295-304, 2014
336 Cruickshank CC, "A review of the clinical pharmacology of methamphetamine" 104 : 1085-1099, 2009
337 Xie Z, "A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain" 330 : 316-325, 2009
338 Hashimoto K, "A neurotoxic dose of methamphetamine induces gene expression of Homer 1a, but not Homer 1b or 1c, in the striatum and nucleus accumbens" 51 : 227-232, 2007
339 Sato M, "A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis" 654 : 160-170, 1992
340 Takigawa M, "A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia" 71 : 321-325, 1993
341 Fantegrossi WE, "A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse" 151 : 533-543, 2008
342 Ren Q, "7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine" 231 : 159-166, 2014
343 Roberts AC, "6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine" 14 : 2531-2544, 1994